Metadata language
Nowe leki otrzymywane przy udziale technologii rekombinowanego DNA
Subtitle:New drugs based on recombinant DNA technology
Creator: Publisher:Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN
Date issued/created: Subject and Keywords: Abstract:Over the last 20 years, some 100 biopharmaceuticals have gained marketing authorization in Europe, USA and other world regions. All biopharmaceu- tical products currently approved within the EU are protein-based. The majority of the first generation products were either unmodified monoclonal antibodies or proteins used clinically to either replace or augment levels of native human proteins. With the recent advances in genomics, proteomics, pharmaceutical target validation, and lead compound identification new perspectives of bio- pharmaceutical products development emerged. Protein engineering has recently facilitated the rational development of a number of proteins displaying an altered pharmacokinetics, biodistribution and therapeutic properties. New strategies and challenges in biopharmaceuticals developments yielded the second generation of protein drugs.
Relation:Biotechnologia, vol.66, 3 (2004)-.
Volume: Issue: Start page: End page: Resource type: Detailed Resource Type: Format: Resource Identifier: Source:Biblioteka Instytutu Chemii Bioorganicznej PAN
Language: Language of abstract: Temporal coverage: Rights:Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0
Terms of use: Digitizing institution:Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Original in:Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Projects co-financed by: Access: